Injecto A/S - CVR: 38729888

2022, DKK

22.01.2024

Bruttoresultat

-1.585'

Primær drift

-2.061'

Årets resultat

-2.627'

Aktiver

3.955'

Kortfristede aktiver

1.892'

Egenkapital

3.382'

Afkastningsgrad

-52 %

Soliditetsgrad

86 %

Likviditetsgrad

330 %

Resultat

22.01.2024

Årsrapport	2022 22.01.2024	2021 02.02.2023	2020 31.01.2022	2019 09.02.2021	2018 06.02.2020	2017 05.02.2019
Nettoomsætning
Bruttoresultat	-1.585.250	-2.931.492	-1.984.229	-2.457.897	0	0
Resultat af primær drift	-2.060.895	-3.790.845	-2.372.621	-2.457.897	-18.580	-15.200
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0
Finansielle indtægter	3.995	0	0	0	0	0
Finansieringsomkostninger	-569.686	-295.573	-172.161	-50.770	-12.222	-33
Andre finansielle omkostninger	0	0	0	0	0	0
Resultat før skat	-2.626.586	-4.086.418	-2.544.782	-2.508.667	-30.802	179.020
Resultat	-2.626.586	-4.086.418	-2.544.782	-2.508.667	-30.802	179.020
Forslag til udbytte	0	0	0	0	0	0

Aktiver

22.01.2024

Årsrapport	2022 22.01.2024	2021 02.02.2023	2020 31.01.2022	2019 09.02.2021	2018 06.02.2020	2017 05.02.2019
Kortfristede varebeholdninger	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	852.751	577.321	110.115	1.531.174	1.552.583	1.500.000
Likvider	1.039.353	104.021	95.084	60.667	273.865	400.715
Kortfristede aktiver	1.892.104	681.342	205.199	1.591.841	1.826.448	1.900.715
Immaterielle aktiver og goodwill	0	0	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0	0	0
Materielle aktiver	2.063.048	1.761.769	2.018.703	1.194.540	1.194.540	880.878
Langfristede aktiver	2.063.048	1.761.769	2.018.703	1.194.540	1.194.540	880.878
Aktiver	3.955.152	2.443.111	2.223.902	2.786.381	3.020.988	2.781.593

Aktiver

22.01.2024

Passiver

22.01.2024

Årsrapport	2022 22.01.2024	2021 02.02.2023	2020 31.01.2022	2019 09.02.2021	2018 06.02.2020	2017 05.02.2019
Forslag til udbytte	0	0	0	0	0	0
Egenkapital	3.381.765	-6.991.649	-2.905.231	-360.449	2.148.218	2.179.020
Hensatte forpligtelser	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	313.240	171.477	117.125	94.525	210.500	327.138
Kortfristede forpligtelser	573.387	9.434.760	5.129.133	3.146.830	872.770	602.573
Gældsforpligtelser	573.387	9.434.760	5.129.133	3.146.830	872.770	602.573
Forpligtelser	573.387	9.434.760	5.129.133	3.146.830	872.770	602.573
Passiver	3.955.152	2.443.111	2.223.902	2.786.381	3.020.988	2.781.593

Passiver

22.01.2024

Nøgletal

22.01.2024

Årsrapport	2022 22.01.2024	2021 02.02.2023	2020 31.01.2022	2019 09.02.2021	2018 06.02.2020	2017 05.02.2019
Afkastningsgrad	-52,1 %	-155,2 %	-106,7 %	-88,2 %	-0,6 %	-0,5 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-77,7 %	58,4 %	87,6 %	696,0 %	-1,4 %	8,2 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-361,8 %	-1.282,5 %	-1.378,1 %	-4.841,2 %	-152,0 %	-46.060,6 %
Soliditestgrad	85,5 %	-286,2 %	-130,6 %	-12,9 %	71,1 %	78,3 %
Likviditetsgrad	330,0 %	7,2 %	4,0 %	50,6 %	209,3 %	315,4 %

Resultat

22.01.2024

Gæld

22.01.2024

Årsrapport

22.01.2024

Nyeste:01.09.2022- 31.08.2023(offentliggjort: 22.01.2024)

Information om virksomhedens regnskabsklasse:The annual report of Injecto A/S for 2021/22 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

22.01.2024

Dato for ledelsens godkendelse af årsrapporten:2024-01-15

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Injecto A/S for the financial year 1 September 2022 - 31 August 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Injecto A/S develops, manufactures, and sells components for pharmaceutical packaging mainly for pre-fillable injection systems (“PFS”) on the basis of the licenses on patent rights from the Injecto Group A/S. Injecto A/S’ main focus is the series of lubrigone plunger stoppers for PFS in ISO measurements but also in individual measurements based on specific company wishes, which plunger stoppers ensure a lubrication free PFS, which is in demand from pharma companies specialised in biologics and in medical preparations for sensitive organs such as eyes, ears, central nervous system, brain etc. The company has two established production lines at SP Medical (www. sp-medical. com) as its OEM manufacturer on lubrigone3 plunger stoppers for PFS in respectively a volume of 0. 5 ml and 1. 0 ml (long) and has increased its contacts with the world’s leading pharmaceutical companies and some of the leading manufacturers in PFS. Injecto A/S’ investment in a third production line for lubrigone stoppers for 1-3 ml PFS in ISO measurements in addition to the two aforementioned production lines, which production is being implemented and validated, ensures that Injecto A/S’ can supply samples in all three basic ISO measurements of PFS for tests from an industrial production to pharma customers and at the same time offer the pharma customers industrial supplies without bottlenecks. Due to Injecto A/S’ strong competitive edge related to the flexibility and efficient production based on the lubrigone concept Injecto A/S can offer the pharma companies and companies in other business area like diagnostics a strong value proposition with respect to the development of the best individual solution and with a much shorter timeline related to a production in industrial scale. It should be noted that Injecto A/S’ products are supplied to primary packaging for pharma, which supplies are defined by extensive testing and hence longer lead times. The longer lead times are matched by long-term lucrative contracts. By the three industrial production lines Injecto A/S has furthermore verified production times and production costs and has built up a reserve that over the coming years will ensure a substantial revenue and a significant profit without further investments. Injecto A/S has also verified that a further scale-up of Injecto Group A/S’ current yearly production capacity of a two-digit million figure can be increased to a yearly production capacity in a three-digit million figure within 9-12 months. Injecto A/S has also been carrying out the co-operation with PATH and its donators and some pharma companies about the easyject syringe, but dependable on the outcome and the resources Injecto A/S and its parent company will consider if the production and sales and marketing of the easyject syringe shall be carried out by another subsidiary under Injecto Group A/S. If this turned out to be the case Injecto A/S will most likely still produce the lubrigone stoppers to be used in the easyject syringe, where the current plan is an initial yearly production of 50 million stoppers for this syringe.